DL0410

01/01/2021 - "In this study, we examined the protective effects of DL0410 in aging rats and explored the underlying mechanism against oxidative damage and neuroinflammation, which was then validated in LPS-stimulated BV2 microglia. "
01/01/2021 - "Next, we examined the protective effects of DL0410 against oxidative damage and neuroinflammation. "
09/01/2020 - "Together, the results showed that DL0410 is a promising drug candidate for treating AD and possibly other nervous system diseases associated with oxidative stress and neuroinflammation."
01/01/2021 - "DL0410 Alleviates Memory Impairment in D-Galactose-Induced Aging Rats by Suppressing Neuroinflammation via the TLR4/MyD88/NF-κB Pathway."
09/01/2020 - "DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation."

12/01/2015 - "DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice."
07/01/2021 - "DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway."
05/01/2020 - "DL0410 ((1,1'-([1,1'-biphenyl]-4,4'-diyl) bis (3-(piperidin-1-yl) propan-1-one) dihydrochloride) is a multiple-target small molecule that has been found to reverse cognitive impairment in different animal models of AD. "
03/06/2017 - "DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice."

03/06/2017 - "In conclusion, DL0410 could be an effective therapeutic drug for the treatment of dementia, especially Alzheimer's disease."
07/25/2017 - "In our study, we attempted to investigate the influences of P-glycoprotein (P-gp) on DL0410, a novel synthetic molecule for Alzheimer's disease (AD) treatment, for intestinal absorption and blood-brain barrier permeability in vitro and related binding mechanisms in silico. "
08/01/2019 - "DL0410, a dual‑action cholinesterase inhibitor and histamine‑3 receptor antagonist with a novel structural scaffold, may be a potential candidate for the treatment of Alzheimer's disease (AD). "
11/01/2016 - "1,1'-([1,1'-Biphenyl]-4,4'-diyl)bis(3-(piperidin-1-yl)propan-1-one)dihydrochloride (DL0410) is a novel synthetic dual acetylcholinesterase (AChE)/butyrocholinesterase (BuChE) inhibitor, which has shown a potential therapeutic effect on Alzheimer's disease (AD). "
07/26/2017 - "DL0410, containing biphenyl and piperidine skeletons, was identified as an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor through high-throughput screening assays, and further studies affirmed its efficacy and safety for Alzheimer's disease treatment. "

11/01/2016 - "In this study we examined whether DL0410 produced neuroprotective effects in an AD cellular model and an Aβ1-42-induced amnesia mouse model. "
12/01/2015 - "It has been demonstrated that DL0410 could improve memory deficits in both Aβ1-42-induced and scopolamine-induced amnesia in mice. "
03/06/2017 - "In the present study, the capability of DL0410 in ameliorating the amnesia induced by scopolamine was investigated, and its effect on the cholinergic system in the hippocampus and its binding mode in the active site of AChE was also explored. "

11/01/2016 - "In Aβ1-42-treated mice, DL0410 administration significantly ameliorated learning and memory deficits in MWM test and passive avoidance test. "
12/01/2015 - "All the behavioural experimental results showed that DL0410 significantly ameliorated memory deficits. "
12/01/2015 - "It has been demonstrated that DL0410 could improve memory deficits in both Aβ1-42-induced and scopolamine-induced amnesia in mice. "